Organization
Eli Lilly and Company, Lilly Research Laboratories, Indianapolis, United States of America
1 abstract
Abstract
BARICITINIB PROVIDES GREATER IMPROVEMENTS IN PATIENT-REPORTED OUTCOMES ACROSS ALL DISEASE ACTIVITY LEVELS COMPARED TO PLACEBO AND ADALIMUMAB IN RHEUMATOID ARTHRITISOrg: University of Oxford, Botnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Oxford, United Kingdom, Hospital Universitario Marqués de Valdecilla, Department of Rheumatology, Santander, Spain, Chiba University Hospital, Department of Allergy and Clinical Immunology, Chiba, Japan, Eli Lilly and Company, Lilly Research Laboratories, Indianapolis, United States of America, Sorbonne University – Assistance Publique Hôpitaux de Paris, Pitie Salpetriere Hospital, Rheumatology Department, Paris, France,